Shilpa Medicare
#ShilpaMedicare -Out of a total 37.5 lac shares pledged as on date, 27 lac shares have been released from pledge by promoters
Huge positive..this was one overhang that was remaining.. got addressed
Company doing concall with analysts/institutions tomorrow
#ShilpaMedicare -Out of a total 37.5 lac shares pledged as on date, 27 lac shares have been released from pledge by promoters
Huge positive..this was one overhang that was remaining.. got addressed
Company doing concall with analysts/institutions tomorrow
Shilpa Medicare raises over Rs. 297 crore from marquee investors
#ShilpaMedicare #INE790G01031 #Pharmaceuticals #FundRaising #PreferentialAllotment #MarqueeInvestors
#ShilpaMedicare #INE790G01031 #Pharmaceuticals #FundRaising #PreferentialAllotment #MarqueeInvestors
SHILPA MEDICARE: CO HAS LAUNCHED ‘PRUCALSHIL (PRUCALOPRIDE) ORALLY DISINTEGRATING STRIPS 1 MG AND 2 MG’ IN INDIA HAS BEEN APPROVED BY DCGI
#shilpamedicare
#shilpamedicare
US #FDA issues no observation for #ShilpaMedicare’s Bio Analytical Laboratory, Unit 7, Hyd
🚨The Laboratory was inspected by US FDA from Feb 26, 2024 to March 1, 2024
🚨The Laboratory was inspected by US FDA from Feb 26, 2024 to March 1, 2024
#ShilpaMedicare’s marketing partner, Amneal Pharma launches Pemetrexed injection 10 mg/mL in the US market
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
According to IQVIA®, U.S. annual sales for pemetrexed for the 12 months ended February 2024 were $287 million
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
According to IQVIA®, U.S. annual sales for pemetrexed for the 12 months ended February 2024 were $287 million
| #ShilpaMedicare successfully complete Phase 1 Clinical Trial for Recombinant Human Albumin (rHA) 20%. Shows potential as a viable alternative to plasma derived human serum albumi